Fibrocell Science (FCSC) Reports FY17 EPS Loss of $1.33

Note: EPS may not be comparable

Fibrocell Science (NASDAQ: FCSC) reported FY17 EPS loss of $1.33

“We are pleased with the substantial progress of our gene therapy candidates that continues to advance and positions us to achieve important milestones in 2018,” said John Maslowski, President and Chief Executive Officer of Fibrocell. “In January 2018, the U.S. Food and Drug Administration granted us allowance to enroll pediatric patients in the Phase 2 portion of our Phase 1/2 clinical trial of FCX-007 for the treatment of recessive dystrophic epidermolysis bullosa, a key milestone for the program.”

“In addition, we completed necessary pre-clinical studies for FCX-013, our product candidate for the treatment of moderate to severe localized scleroderma. We used the data to support our submission of an Investigational New Drug Application to the FDA in January 2018, and in March, the FDA allowed the IND for FCX-013 to progress to clinical trials,” said Mr. Maslowski.

For earnings history and earnings-related data on Fibrocell Science (FCSC) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Vivos Therapeutics posts 35% revenue gain but widens net loss
• Movano (MOVE) Misses Q2 EPS by 195c